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Following infection, many secreted poxvirus proteins are able to modulate the host immune response through interactions 
with cytokines or components of the complement pathway. A comparison of the secreted protein profiles from cells infected 
with vaccinia Western Reserve (W-WR), cowpox virus Brighton strain, or rabbitpox virus (RPV) showed an abundant 35-kDa 
protein present only in the supernatants from RPV-infected cells. The gene encoding this protein was identified and mapped 
by N-terminal sequencing of the protein. Examination of the predicted amino acid sequence showed it to be identical to 
the 35-kDa secreted protein of the Lister strain of vaccinia virus described bY Patel et aL (1990, J. Gen. ViroL 71, 2013- 
2021). The counterpart of this gene in the commonly studied W-WR strain is truncated and encodes a 7.5-kDa protein 
under control of the well-characterized p7.5 promoter. While nonessential for replication in cell culture, conservation of this 
gene in at least two orthopoxvirus strains suggested that this protein might play an important role in vivo. Following intranasal 
inoculation of Balb/c mice at several doses (103, 104, or 10 S PFU), a mutant of RPV lacking a functional 35-kDa gene 
(RPVA35) appeared to induce an earlier onset and more severe illness at low, sublethal doses (103 PFU) than was observed 
with wild-type (wt) RPV. At higher doses (104 or 10 s PFU), the behavior of wt RPV and RPVA35 became indistinguishable 
and the overall LDso values were similar. Intradermal infection of rabbits simultaneously, at separate sites, with RPV and 
RPVA35 showed no gross or microscopic differences between either primary skin lesions or viremic extension of each 
virus into the lungs. Therefore, this abundant secreted protein does not appear to play a major role in the virulence of the 
virus.  © 1995 Academic Press, Inc. 
INTRODUCTION 
In recent years, a number of poxvirus-encoded pro- 
teins have been shown to interact with components of 
the host inflammatory and immune systems. Deletion of 
such genes frequently results in virus attenuation (see 
Turner and Moyer, 1990; Buller and Palumbo, 1991, for 
reviews). The vaccinia virus (W)-encoded complement 
control protein (VCP, the O21L ORF) acts to inhibit the 
complement cascade (Kotwal and Moss, 1988; Kotwal et 
al., 1990; Isaacs et aL, 1992a). W (the B15R ORF) and 
cowpox virus (CPV) produce a protein which binds to 
interleukin-1/3 (Alcami and Smith, 1992; Spriggs et aL, 
1992). Myxoma virus produces proteins which bind to 
TNF (Upton et al., 1991) and interferon-?, (Upton et al., 
1992) as well as a serpin (SERP-1)which inhibits several 
plasma proteases (Lomas et al., 1993; Macen et al., 
1993). A serpin encoded by CPV (SPI-2 or crmA) acts to 
inhibit the activation of interleukin-1/3 (Ray et al., 1992). 
Other poxvirus proteins, such as the M11L ORF of myx- 
oma virus (Graham et al., 1992; Opgenorth et al., 1992) 
and B5R ORF (ps/hr) of vaccinia and rabbitpox viruses 
(Takahashi Nishimaki et al., 1991; Engelstad et al., 1992; 
~To whom correspondence and reprint requests should be ad- 
dressed. 
Engelstad and Smith, 1993; Isaacs eta/., 1992b; Wolffe et 
al., 1993; Martinez-Pomares et al., 1993), have profound 
effects on viral virulence but specific functions in vivo 
have not yet been ascribed to these proteins. 
Most of these proteins are secreted and found in the 
supernatants from infected cells. Indeed, only the crmA 
(Ray et al., 1992) and M11L ORF of myxoma (Graham et 
al., 1992) are believed to be intracellular or restricted to 
• the surface of the cell. The fact that many viral secreted 
proteins influence virulence suggests that any major se- 
creted viral protein is an excellent candidate for a viral 
gene which might modify the host response to infection. 
Two major secreted proteins are produced by wild-type 
rabbitpox virus (RPV)-infected cells. One of these has 
been previously identified as the RPV (ORF C3L) homolog 
of the VCP protein encoded by the Western Reserve 
strain of vaccinia virus (W-WR) (ORF C21 L) (Bloom et al., 
1991, 1993). However, a second, 35-kDa protein, the most 
abundant protein secreted by this virus, is unique to RPV 
and is not secreted by either W-WR or CPV. We report 
here the identification of that protein and show it is simi- 
lar if not identical to a 35-kDa protein secreted by W-  
Lister (Patel et al., 1990) and related to a much smaller 
protein (7.5 kDa) in W-WR controlled by the intensively 
studied P7.5 promoter, and that like the W-soluble IL- 
1/~ receptor homolog (Spriggs et al., 1992; AIcami and 
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Smith, 1992), the production of this 35-kDa protein by 
RPV may, at low doses, act to retard the onset of illness 
and loss of weight in infected animals. 
MATERIALS AND METHODS 
Viruses and cells 
The wild-type (wt) Utrecht strain of rabbitpox virus and 
vaccinia virus strain WR were obtained from the Ameri- 
can Type Culture Collection. The wild-type Brighton red 
strain of cowpox virus was obtained from Dr. David 
Pickup of Duke University. The white pock deletion mu- 
tant of RPV, RP#hr23, was originally obtained from Frank 
Fenner and has been described in detail (Bloom et aL, 
1991; Edwards etaL, 1988; Moyer eta/., 1980; Moyer and 
Rothe, 1980). CV-1 and RK-13 cells were maintained in 
GIBCO minimal essential medium (MEM) supplemented 
with 5% fetal bovine serum, 2 mM glutamine, 50 units/ 
ml penicillin, 50 #g/ml streptomycin, 1 mM sodium pyru- 
vate, and 0.1 mM MEM nonessential amino acids 
(GIBCO). 
Preparation of supernatants from infected cells 
Monolayers of CV-1 cells in 150-mm dishes were in- 
fected at a moi of 5 in OptiMEM medium supplemented 
with 2 mM glutamine, 50 units/ml penicillin, 50 ffg/ml 
streptomycin, 1 mM sodium pyruvate, and 0.1 mM MEM 
nonessential amino acids (GIBCO) (Opti-MEM + supple- 
ments). One hour after infection the inoculum was re- 
moved, the cells were extensively washed with phos- 
phate-buffered saline, pH 7.2 (PBS), and 20 ml of Opti- 
MEM + supplements was added. The supernatants were 
collected 24 hr later and clarified at 10,000 g at 4°0 for 
60 min. 
Preparation of 35S-labeled secreted protein extracts 
Monolayers of CV-1 or RK-13 ceils were infected at a 
moi of 10 in MEM supplemented with 1% fetal bovine 
serum, 2 mM glutamine, 50 units/ml penicillin, 50 ffg/ml 
streptomycin, 1 mM sodium pyruvate, and 0.1 mM MEM 
nonessential amino acids (GIBCO). Radiolabeling of viral 
proteins was achieved by replacing the media with MEM 
containing 50 ffCi/ml of [35S]Translabel (ICN Biomedicals, 
inc.) and one-tenth the usual content of methionine and 
cysteine. The supernatants were collected at the end of 
the labeling period. 
Protein microsequencing 
Protein microsequencing was done in collaboration 
with the protein core facility of the Interdisciplinary Cen- 
ter for Biotechnology Research (ICBR) of the University 
of Florida. Supernatants from Mock- and wt RPV-infected 
CV-1 cells were prepared as described previously, con- 
centrated X 100 using a Centriprep-10 concentrator (Ami- 
con), and electrophoresed in a sodium dodecyl sulfate- 
polyacrylamide gel (SDS-PAGE) consisting of a 4% 
acrytamide stacking gel and a 10% separating gel. Fol- 
lowing electrophoretic separation, proteins in the un- 
stained gel were transferred overnight at 4°0 to a Problot 
membrane at 20V in a buffer containing 10 mM MES, pH 
6, and 20% methanol. Proteins were visualized on the 
membrane by staining with 0.02% Coomassie blue in 40% 
methanol and 5% acetic acid. The membrane was then 
washed with distilled water and air-dried. The band cor- 
responding to the RPV 35-kDa secreted protein was cut 
from the membrane and microsequenced using an Ap- 
plied Biosystems gas-phase sequencer. 
Construction of a mutant disrupted in the gene 
encoding the 35-kDa protein (RPVA35) 
The plasmid pD357 (Patel etaL, 1990) contains a frag- 
ment of W-Lister DNA where the 35-kDa protein is de- 
leted and replaced by the /~-galactosidase gene under 
control of the 35-kDa protein promoter (p7.5 in W-WR) 
flanked by viral sequences upstream (~1500 bp) and 
downstream (~250 bp) of the replaced W-Lister 35-kDa 
gene. The plasmid was used for the construction of the 
recombinant RPV carrying the fl-galactosidase gene as 
a complete replacement for the 35-kDa gene and was 
kindly provided by Dr. Nigel D. Stow. Monolayers of CV- 
1 cells in 60-mm dishes were transfected with 10 fig 
of plasmid pD357 as described previously (Turner and 
Moyer, 1992). The selection of RPV mutants lacking the 
35-kDa protein (RPVZ&35) was done by plaque purifica- 
tion in the presence of 150 #g/ml of 5-bromo-4-chloro-3- 
indolyl-/3-u-galactopyranoside (X-gal) until no further seg- 
regation of "white" plaques was observed. The putative 
recombinant virus was amplified in RK-13 cells and fur- 
ther analyzed as described in the text. 
Animals and infections 
Female Balb/c mice (Harlen, Sprague-Dawley, Inc., 
Indianapolis, IN) were 6 to 8 weeks old, virus free, and 
weighed between 16 and 20 g. Intranasal virus infection, 
blood and organ collection, and virus titrations were per- 
formed as previously described (Thompson et al., 1993). 
Infectious doses ranged from 102 to 106 plaque forming 
units (PFU) and the LDso was determined by the method 
of Reed and Meunch (Reed and Meunch, 1938). Virus 
titers were verified before and following each experiment 
involving animals to ensure the accuracy of the doses 
administered. 
Adult female, New Zealand White rabbits (M & P Rab- 
bits, Bronson, FL) were inoculated intradermally in four 
sites with 0.1 ml PBS containing 500 PFU of wt RPV along 
the left side of the back and in four sites with 500 PFU 
of RPVA35 along the right side of the back; a single 
intradermal injection of 0.1 ml PBS was used as a nega- 
tive control. The rabbits were observed twice daily for the 
development of cutaneous lesions and systemic signs of 
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illness. A 6-mm diameter Baker's biopsy punch (Baker 
Cummins Pharmaceuticals, Inc., Miami, FL) was used to 
obtain skin specimens at 3, 5, and 7 days after inocula- 
tion from individual injection sites for microscopic exami- 
nation. Rabbits that became moribund during the infec- 
tion were euthanatized by intravenous injection of so- 
dium pentobarbital. 
Quantitation of interleukin-6 and tumor necrosis 
factor 
Four groups of six mice were infected intranasally with 
10 4 or 10 6 PFU of either RPVZ&35 or RPV. An additional 
group of six mice served as negative controls and were 
inoculated intranasally with PBS only. At 3 and 5 days 
after infection, three mice within each group were bled 
to obtain serum for quantitation of interleukin-6 (IL-6) and 
tumor necrosis factor (TNF). The mice were sacrificed by 
cervical dislocation immediately after collecting a blood 
specimen. The trachea was then exposed, through a ven- 
tral cervical incision, and cannulized with a nasal-lacri- 
mal needle through a small incision made between two 
adjacent tracheal rings. The nasal-lacrimal needle was 
secured within the tracheal lumen by a simple inter- 
rupted suture which surrounded the trachea. One millili- 
ter of PBS was then injected through the nasal-lacrimal 
needle and then aspirated back into a 3-ml syringe twice 
to lavage the trachea, bronchi, and lower airways. A 
monoclonal antibody capture ELISA was used to mea- 
sure serum and intrapulmonary IL-6 (Pharmingen, San 
Diego, CA) and TNF (Pharmingen) concentrations; re- 
combinant mouse TNF-~ (Genzyme Diagnostics, Cam- 
bridge, MA) and IL-6 (Pharmingen) were used to estab- 
lish standard curves for the ELISA assays. 
RESULTS 
Characterization of the major secreted proteins from 
wt RPV-, CPV-, and W-WR-infected cells 
A comparison of the major proteins present in the me- 
dia from mock-, RPV-, CPV-, and W-WR-infected cells 
showed that each of these poxviruses produced a differ- 
ent profile of secreted proteins (Figs. 1A and 1B). Proteins 
of the same molecular weight as VCP (29 kDa), the major 
W-WR secreted protein and a homolog of the C4b bind- 
ing protein of complement (Isaacs eta/., 1992a; McKenzie 
etaL, 1992; Kotwal eta/., 1990; Kotwal and Moss, 1988) 
were also found in the supernatants from RPV- and CPV- 
infected cells. In the case of RPV this 29-kDa protein 
(RPV ORF C3L) has been shown to be the RPV homolog 
of the vaccinia VCP since= (1) The 29-kDa protein was 
recognized by antibodies raised against VCP (data not 
shown); (2) the 29-kDa protein was absent in the super- 
natants from cells infected with RPV#hr23 which does 
not contain the gene coding for the VCP (Fig. 1B); and 
(3) the 29-kDa protein was present in the supernatants 
84 kDa- 
64 kDa- 
55 kDa- 
30 kDa- 
A B 
RPV 
Mock RPV CPV W Mock ~3 wt W 
-106 kDa 
~7,4 kDa 
-66kDa 
-45 kDa 
-29 kDa 
FIG. 1. Analysis of proteins secreted by several poxvirus-infected 
cells. (A) Analysis of 35S-labeled proteins present in the supernatants 
from mock-, RPV-, CPV-, or W-WR-infected RK-13 cells. Continuous 
radiolabeling ofnewly synthesized proteins was done as described 
under Material and Methods from 6 to 12 hr pi. After labeling, cell 
supernatants were collected, clarified by centrifugation at 11,600 g for 
15 min, and analyzed on a 10% SDS-polyacrylamide gel. (B) Coomassie 
blue staining of proteins secreted by mock-, RPV ~, RPV#hr23-, or WWR- 
infected CV-1 cells. Supernatants were prepared as described under 
Materials and Methods and concentrated x 40 using a Centriprep- 
10 before separation of proteins on SDS-polyacryiamide gels. Sixty 
microliters of the concentrated supematants were loaded in each lane. 
Repeated freezing and thawing led to breakdown of the 35-kDa protein 
(data not shown). Molecular weights are shown in the margins. 
from the recombinant virus #23Eco3 (Bloom eta/., 1991), 
which contains a copy of the C3L RPV gene (data not 
shown). One additional major protein was present in the 
supernatants from both RPV- and CPV-infected cells (Fig. 
1A). In the case of CPV, the unique protein was smaller 
and more that the putative VCP. In RPV-infected cell su- 
pernatants, the additional protein was also more abun- 
dant than VCP and larger, with an apparent molecular 
weight of 35 kDa. This 35-kDa protein was also secreted 
by RPV#hr23-infected cells and was easily detected in 
both RPV- and RPV#hr23-infected, concentrated cell su- 
pernates by Coomassie blue staining (Fig. 1B). 
Mapping the gene coding for the RPV 35-kDa 
secreted protein 
Identification of the gene encoding the RPV major se- 
creted protein was achieved through direct sequencing 
of the N-terminus of the protein (see Materials and Meth- 
ods), which yielded the sequence MPASLQQSS. Screen- 
ing of databases revealed the identical sequence in a 
protein described previously (Patel eta/., 1990) as a 35- 
kDa major secreted protein of the Lister strain of W. In 
the Lister strain, the gene was mapped and shown to be 
present in two copies within both inverted terminal re- 
peats (Patel eta/., 1990). It was also shown that this 
protein was not required for W-Lister growth in tissue 
culture. Using primers, based on internal 5' and 3' se- 
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FiG. 2. Characterization of RPVA35 mutants. (1) Schematic represen- 
tation of the structure of the 35-kDa gene in wt RPV and interruption 
of the gene by the /~-galactosidase gene to generate the RpVA35 
mutant. (2) Southern blot analysis of wt RPV (wt) and three indepen- 
dently isolated RPVz&35 mutants. Purified viral DNAs were digested 
with Hindlll, separated by electrophoresis in agarose gels, and trans- 
ferred to a nylon membrane. The membranes were hybridized to a 32p_ 
labeled PCR-amplified 35-kDa protein gene (A) or to the 32p-labeled/~- 
galactosidase gene (B). The terminal host Hindlll B and C fragments 
are indicated. 
quences of the W-Lister 35-kDa protein gene sequence, 
it was possible with PCR to amplify an RPV gene homolog 
from RPV DNA. This 800-bp PCR product hybridized to 
both the RPV Hindl l l  B- and C-terminal restriction frag- 
ments located at both extremes of the viral DNA, indicat- 
ing the presence of two copies of the gene (Fig. 2A). In 
W-Lister, the expression of this gene is under the control 
of the strong early/late PT.~ promoter (Patel et al., 1990; 
Cochran et al., 1985), which in W-Wfq controls expres- 
sion of a truncated (7.5-kDa) version of this protein (Coo- 
per et al., 1981b). Based on (1) the successful amplifica- 
tion of an RPV sequence of appropriate size using PCR 
primers from the W-Lister sequence, (2) the size of the 
PCR product, (3) the relative molecular weight of the pro- 
tein, (4) its secretion into the media, and (5) its synthesis 
at both early and late times postinfection (Fig. 4), it be- 
comes apparent that he RPV 35-kDa protein and that 
described for the W-Lister strain are very similar if not 
identical. 
As final proof, a plasmid containing the /~-galactosi- 
dase gene flanked by portions of the W-Lister 35-kDa 
protein gene (external to the 800-bp probe discussed 
above) was used to transfect RPV-infected cells. The 
plasmid (provided by Dr. Nigel Stowe) was designed by 
them to replace the 35-kDa gene by the/~-galactosidase 
gene in W-Lister. RPV recombinants containing the ~- 
galactosidase gene were selected by repeated picking 
of individual RPV plaques which stained blue in the pres- 
ence of Xgal and were stable to segregation (see Materi- 
als and Methods). DNA analysis of several of these re- 
combinants, showed they lacked both copies of the 35- 
kDa homolog of the W-Lister and instead contained two 
copies of the /3-galactosidase gene consistent with the 
expected replacement of a diploid 35-kDa gene with /:F- 
galactosidase (Fig. 2B). We refer to this mutant(s) as 
RPVA35. Finally, when secreted protein patterns from 
RPV and RPVA35 were compared, the major RPV 35- 
kDa protein secreted at both early and late times in RPV- 
infected ceils was completely absent in supernatants of 
cells infected with RPVz&35 (Fig. 4). Based on these re- 
sults, there is little doubt that the RPV 35-kDa secreted 
protein is the homolog of the W-Lister protein. 
As shown in Figure 3, the gene encoding the W-Lister 
strain 35-kDa protein is not only well conserved among 
several orthopoxviruses (variola; Massung et aL, 1993), 
OPV (Pickup et aL, 1982), and W-Copenhagen (Goebel 
et al., 1990), but also in Shope fibroma virus (SFV), a 
leporipoxvirus (Upton et aL, 1987). In all these cases, the 
predicted proteins are highly hydrophilic and acidic (p/ 
ranging from 4.29 to 4.64). The W-Lister, CPV, variola, 
and SFV proteins contain an N-terminal hydrophobic re- 
gion which in the case of the Lister strain acts as a signal 
peptide (Patel et aL, 1992). Our direct sequencing of the 
N-terminal portion of the 35-kDa RPV protein suggests 
that this hydrophobic region is also removed during the 
secretion of the RPV protein (Fig. 4). We would predict 
that the variola protein is secreted as well, but that the 
W-Copenhagen homolog, which lacks the putative sig- 
nal peptide, is not. A second W-WR protein related to 
the SFV T10RF was discovered earlier (Howard et aL, 
1991). This ORF, named SaIF-4L, encodes a 219-amino- 
acid protein with a predicted molecular weight of 25 kDa 
and also contains a potential signal sequence. However, 
this 25-kDa protein does not share significant homology 
with the family of 36-kDa protein genes described here, 
Indeed, as mentioned, the 35-kDa protein gene homolog 
in W-WR is truncated and yields only a 7.5-kDa protein 
(Patel et aL, 1990). It is curious to note that CPV does 
not secrete a 35-kDa protein as might be expected from 
the primary amino acid sequence (246 amino acids) 
(Pickup et aL, 1982) which is very similar to that of W- 
Lister (258 amino acids) (Patel etaL, 1990) shown in Fig. 
3. CPV does, however, produce a unique, very abundant 
smaller secreted protein (Fig. 1). Whether this protein is 
related to the secreted 35-kDa protein of RPV has not 
been established. 
The contribution of the RPV 35-kDa protein to growth 
in cell culture 
Although the 35-kDa protein is conserved among sev- 
eral poxviruses, including variola, its alteration in two 
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Consen. MKQ. IVLAC .CLAA.A .PA  SLOOS.~S$S SCTEEENKHH MGIDVI IKUT 
Copenh . . . . . . . . . . . . . . . .  MHVPA SLOOSSSSSS SCTEEENKHH MGIDVI IKVT  
Lister .MKQYIVLAC MCLAAAAMPA SLOOSSSSSS SCTEEENKHH MGIDVI IKVT  
Variola .MKQYIVLAC MCLAAAPA SLO0. . .SSS  SCTEEENKHY MGIDVI IKVT  
Cowpox .MKQ. IVLAC ICLAAVAI£T  SLOOSFSSSS SCTEEENKHH MGIDVI IKVT  
: I:L: A A C :E : MGIDV: :DVT 
SFV MRRLCI ILLV  YVYATFA . . . . . . . . . .  TKG ICKQDEDVRY MGIDVVVKVT 
KQDQTPTNDK 
KQDQTPTNDK 
KQDQTPTNDK 
KQDQTPTNDK 
KQDQTPTNDK 
K T D 
K . .KTSGSDT 
Consen. ICQSVTE ITE  SES . .DPEVE 
Copenh. ICQSVTE ITE  SESDPDPEVE 
Lister ICQSVTE ITE  SESDPDPEVE 
Variola ICQSVTE ITE  SES . .DPEVE 
Cowpox ICQSVTEVTE SEDESEEVVK 
:CQ : E D : 
SFV VCQALRTTFE AAHKGDGAND 
S . . . . . . . . . . . . . . .  EDDS TSVEDVDPPT 
S . . . . . . . . . . . . . . .  EDDS TSVEDVDPPT 
S . . . . . . . . . . . . . . .  EDDS TSVEDVDPPT 
S . . . . . . . . . . . . . . .  EDDS TSVEDVDPPT 
G . . . . . . . . . . . . . .  ".D . . . . . . . . . . .  PT 
S E D : :E :: 
SLSTEYVDDY SEEEEYEYDE SFLEGFVIGS 
TYYS I IGGGL 
TYYS I IGGGL 
TYYS I IGGGL 
TYYS I IGGGL 
TYYTVVGGGL 
TYY: : :GGGL 
TYYT IVGGGL 
Consen RMNFGFTKCP Q IKS ISESAD 
Copenh.  RMNFGFTKCP Q IKS ISESAD 
Lister RMNFGFTKCP Q IKS ISESAD 
Var io la  RMNFGFTKCP Q IKS ISESAN 
Cowpox TMDFGFTKCP K ISS ISEYSD 
FGFT CP :KS:SE A 
SFV SVTFGFTGCP TVKSVSEYAK 
GNTVNARLSS VSPGQGKDSP A ITREEALAM 
GNTVNARLSS VSPGQGKDSP A ITREEALAM 
GNTVNARLSS VSPGQGKDSP A ITREEALAM 
GNAVNARLSS VPLGQGKDSP A ITRAEALAM 
GNTVNARLSS VSPGQGKDSP A ITREEALSM 
G V :RLSS P I R EALA:  
GRIVF IRLSS DAPWRDTNPM S INRTEALAL  
IKDCE.S ID I  
IKDCEVSID I  
IKDCEVSID I  
IKDCELS ID I  
IKDCEMSIN I  
: CE SIDI  
LEKCETS ID I  
Consen RCSEEEKDSD IKTHPVLGSN 
Copenh, RCSEEEKDSD IKTHPVLGSN 
Lister RCSEEEKDSD IKTHPVLGSN 
Varie la RCSEEEKDSD IQTHPVLESN 
Cowpox KCSEEEKDSN IKTHPVLGSN 
:CS E L 
SFV KCSNETVSET TYGLASLAPH 
ISHKKVSYED I IGST IVDTK CVKNLEFSUR 
ISHKKVSYED I IGST IVDTK CVKNLEFSVR 
ISHKKVSYED I IGST IVDTK CVKNLEFSVR 
ISHKKVSYED I IGST IVDTK CVKNLEFSVR 
ISHKKVSYED I IGST IVDTK CVKNLE ISVR 
I: I IGST:VDT CV NL : : :V :  
ITQATER.GN I IGSTLVDTD CVENLDVTVH 
IGDMCKESSE 
IGDMCKESSE 
IGDMCKESSE 
IGDMCKESSD 
IGDMCKESSE 
:G:MC: :S: 
LGEMCRKTSD 
Consen LEVKDGFKYV DGSASEGATD DTSL IDSTKL  KACV 
Copenh.  LEVKDGFKYV DGSASEGATD DTSL IDSTKL  KACV 
Lister LEVKDGFKYV DGSASEGATD DTSL IDSTKL  KACV 
Vario la LEVKDGFKYV DGSVSEGVTD DTSL IDSTKL  KSCV 
Cowpox LEVKDGFKYV DGSASEDAAD DTSL INSAKL  IACV 
L :D :KY G E : D DT I : KL KAC 
SFV LSKRDSLKVK NG. . .ELLDD DTFS IHTPKL  KACN 
RG. 3. Comparison of the amino acid sequences of the 35-kDa major secreted protein from the W-Lister strain (Patel et aL, 1990) and comparable 
homotogs in the W-Copenhagen ORFs 023L and B19R (Goebel eta/., 1990), variola virus, ORF G5R (Massung eta/., 1993), CPV, and the SFV, ORF 
T1 (Upton et al., 1987). A consensus sequence was deduced from the W-Lister and W-Copenhagen strains, cowpox, and vadola sequences. This 
consensus sequence was then compared to the SFV sequence and identities and/or conservative changes between the SFV and orthopoxvirus 
consensus sequences are shown. The amino acid sequence obtained from the RPV 35-kDa protein by direct sequencing is underlined in the 
sequences. 
orthopoxvirus strains highly passaged in cell culture (W- 
WR and W-Copenhagen) but otherwise perfectly viable, 
suggests that this protein is nonessential for growth in 
cell culture. Truncation of the protein to 7.5 kDa in W-  
WR and loss of the signal portion of the protein in W-  
0openhagen could simply be a manifestation resulting 
from the fact that these intensively studied strains have 
also been among the most extensively passaged strains 
in cell culture. As was demonstrated for W-Lister, we 
have shown the 35-kDa protein of RPV is not required 
for growth in a variety of cell lines in culture. The cell lines 
examined include rabbit (RK-13), human (A549), chicken 
embryo fibroblasts, swine (PK-15), monkey (CV-1), and 
rodent (RAT-2) ceils. The RPVA35 mutant produced nor- 
mal titer stocks and plaques that were indistinguishable 
from RPV. Finally, the RPVA35 mutant produced red, 
hemorrhagic pocks on the chorioallantoic membrane of 
embryonated eggs which were indistinguishable from 
those of RPV (data not shown). Nevertheless, as dis- 
cussed earlier, the involvement of several secreted pro- 
teins in viral virulence and pathogenesis implied that this 
protein could also play an important role in the in viva 
pathogenesis of the virus. 
The in viva role of the 35-kDa protein in pathogenesis 
in infected mice 
We have developed a model for the intranasal infection 
of Balb/c mice by RPV which has been useful in our 
studies to ascertain the contribution of specific genes to 
viral pathogenesis (Bloom et al., 1991; Thompson et al., 
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49.5 kDa- 
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18.5 kDa- 
FIG. 4. Characterization of the proteins secreted by RPVA35-infected 
cells. RK-13 cells were mock-infected or infected with wt RPV or 
RPV/',35 and labeled as described under Materials and Methods from 
0 to 6 (Early) or from 6 to 12 hr pi (Late). After labeling supernatants 
were collected, clarified, and electrophoresed in a 10% polyacrylamide- 
SDS gel. Molecular weight markers are shown. 
1993). Following the procedures described previously 
(Thompson et al., 1993), 40 mice, separated into groups 
of eight, were infected intranasally with RPVz&35 using 
10-fold serial dilutions of virus which ranged from 102 to 
106 PFU. Another group of mice was infected with RPV. 
Eight mice served as negative controls and were inocu- 
lated with PBS only. Mice were examined twice daily for 
clinical signs of illness. Body weight was recorded daily, 
and blood was sampled 4 and 6 days after infection to 
measure viremia. 
Mice infected with 102 PFU of either RPVA35 or RPV 
showed no decrease in body weight nor clinical signs 
of illness following intranasal infection. Mice infected 
with 103 PFU of RPVA35 exhibited detectable (P < 0.05) 
weight loss and clinical signs of illness manifested by 
ruffled fur, decreased activity, increased huddling, and 
tachypnea. All mice eventually recovered. However, mice 
infected with 103 PFU of RPV remained healthy and 
showed neither clinical signs of illness nor weight loss 
(Fig. 5). Mice infected with 104 PFU of RPVA35 appeared 
to exhibit a somewhat more severe and rapid onset of 
illness, as well as a more substantial loss of weight 
compared to mice infected with 104 PFU of RPV (Fig. 5) 
but these differences were small. Ultimately, however, 
the clinical signs of illness became identical in the two 
groups of mice. All mice infected with 104 of either 
RPVA35 or RPV eventually recovered. However, four of 
eight mice infected with 106 PFU of RPVA35 and two of 
eight mice infected with RPV succumbed 7-9 days after 
infection. Infection with 106 PFU of either RPVA35 or RPV 
was uniformly lethal; however, once again, the disease 
manifestations were more rapid and more severe in mice 
infected with RPVA35, as six of eight mice succumbed 
by Day 6 after infection as compared to RPV where only 
one of eight mice had succumbed. The lOgic LD6o of 
RPVA35 and RPV was 5.0 and 5.3, respectively. 
Viremia was evaluated 4 and 6 days after infection 
with 10 4 and 106 PFU of RPVA35 and RPV. Viremia was 
detected in the majority of mice and there was no signifi- 
cant difference noted with either virus (Table 1). Viremia 
persisted />6 days after infection at both doses and, in 
general, larger intranasal infectious doses resulted in 
higher levels of virus within the circulating blood. 
Surviving mice infected with 10 4 PFU of RPV or 
RPVA35 at Day 13 of the infection were sacrificed. The 
brain and lungs were collected and virus titers were de- 
termined. No virus was found within the brain and only 
4 of 16 mice had virus within the lungs (Table 1). In 
contrast, all mice infected with 10 6 PFU of either RPV or 
RPVA35 succumbed within 5-10 days following inocula- 
tion. The brain and lungs of these mice were collected 
within 24 hr of-death and assayed for virus. All mice 
exhibited virus extension to the brain and had high con- 
centrations of virus within the pulmonary parenchyma 
(Table 1). There was no statistical difference between 
titers in the organs of mice infected with either RPVA35 
or RPV. 
Because our initial pathogenesis studies in mice dem- 
onstrated a conspicuous absence of inflammatory cells 
associated with intranasal RPV infection (Thompson et 
a/., 1993) and because many poxvirus proteins secreted 
from infected cells can inhibit cytokine activity, we 
wished to measure the effect of local secretion of the 
35-kDa protein from RPV-infected cells on local and sys- 
temic cytokine activity. Since an ordered cascade rela- 
tionship has been observed for TNF, IL-1, and IL-6, in 
that TNF induces IL-1 production which then leads to 
synthesis of IL-6 (Abbas eta/., 1991), we elected to mea- 
sure intrtapulmonary and serum concentrations of TNF 
and IL-6 following intranasal infection with RPV and 
RPVA35. 
Intrapulmonary and serum concentrations of IL-6 and 
TNF following intranasal infection with RPVA35 and RPV 
revealed no significant biological differences between 
these viruses (data not shown). Intrapulmonary concen- 
trations of IL-6 were, however, in all cases, significantly 
(P < 0.5) higher following infection with 106 PFU of virus 
as compared to 10 4 PFU of virus. The mean concentra- 
tions _+SD were 160 ± 60 and 130 + 40 pg/ml in mice 
infected with 10 4 PFU of RPV and RPVA35, respectively, 
as compared to IL-6 concentrations of 1110 + 880 and 
1750 _+ 220 pg/ml in mice infected with 106 PFU of RPV 
and RPVA35, respectively. Negative control mice inocu- 
lated with PBS exhibited intrapulmonary IL-6 concentra- 
tions of 160 +_ 60 pg/ml. 
Viral pathobiology in rabbits 
Two adult rabbits were inoculated intradermally with 
RPV in four sites (500 PFU/site) along the left side of the 
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with PBS is also shown (open squares). The line indicates times at which significant differences between the RPVA35 and wt RPV infections were 
noted. ID, infectious dose. Results are plotted as mean change body weight (g) + SD versus days after infection. 
back and in four sites with an identical dose of RPVA35 
along the right side of the back. A single intradermal 
injection of PBS was used as a negative control. Erythem- 
atous foci, 5 -10  mm in diameter, were observed at each 
virus injection site 2 days after intradermal inoculation. 
By 3 days after injection, the cutaneous lesions exhibited 
erythema and induration, measured 10-20 mm in diame- 
ter, and contained a 3- to 5-mm-diameter, central white 
area. The PBS control injection sites revealed no cutane- 
ous lesions. By 5 days after inoculation, the central white 
area of the lesions varied in color from yellow-tan sur- 
rounded by a distinct erythematous rim to dark, red- 
black; these central lesions measured 5 -10  mm in diam- 
eter and were surrounded by erythema and induration 
which measured 20-30  mm in diameter. The lesions 
were considered painful as the rabbits showed exces- 
sive cutaneous muscle twitching when the lesions were 
touched. The lesions exhibited little change between 5 
and 7 days after inoculation, except the central areas 
became uniformly dark, red-black in color. At no time 
was a detectable difference observed between intrader- 
mal sites inoculated with RPV and RPVA35. 
Biopsies of the cutaneous lesions were obtained 3, 5, 
and 7 days after inoculation. Microscopic examination of 
these biopsies revealed no differences between lesions 
associated with RPV and RPVA35 inoculation. At 3 days 
after infection the microscopic changes consisted of a 
mild periadnexal and dermal infiltration of a population 
of mixed inflammatory cells comprised predominantly of 
heterophils. By 5 days inoculation the numbers of hetero- 
phils within the dermis had increased, a l ichenoid band 
of heterophils had formed beneath the basal epithelial 
cells, and vacuolar degeneration of the basal epithelial 
cells was prominent; heterophils were also observed 
within the basal epithelial cell layer and a distinct subcor- 
neal vesicle with minimal accumulations of heterophils 
was also noted. By 7 days after inoculation the skin ex- 
hibited severe dermal necrosis, hemorrhage, and edema 
formation. Well-developed subcorneal pustules were 
present and necrosis of the basal epithelial cells and 
adnexal structures was severe. 
Systemic illness and viremia developed in both rabbits 
fol lowing intradermal inoculation. Viremia was readily in- 
dicated bythe appearance Of lesions in the ears. Pyrexia 
was the first sign of systemic illness and was apparent 
2 days after infection. Addit ional systemic signs included 
TABLE 1 
BIOLOGICAL COMPARISON OF RPVA35 AND RPV AFTER INTRANASAL INOCULATION 
Biologic parameter ~
104 PFU infectious dose 10 G PFU infectious dose 
RPVA35 RPV RPVA35 RPV 
Viremia 
Day 4 2.2 _+ 0.1 (2/8) b 2.1 4- 0.1 (5/8) 2.5 + 0.4 (8/8) 2.8 _+ 0.3 (7/8) 
Day 6 2.0 _+ 0.1 (2/8) 2.2 _+ 0.2 (4/8) 4.0 (1/2) 2.8 _+ 0.3 (5/7) 
Organ viral titer 
Brain <2.5 (0/8) <2.5 (0/8) 5.5 _+ 1.0 (8/8) 5.5 _+ 1.0 (8/8) 
Lung 4.5 _+ 1.1 (3/8) 4.7 (1/8) 8.9 _+ 0.7 (8/8) 8.7 _+ 0.3 (8/8) 
a Viremia and organ virus titer expressed as the logic mean PFU/ml blood _+ SD and logic mean PFU/g tissue of mice exhibiting detectable virus, 
respectively. The lOgic level of virus within the blood and organs was 1.6 PFU/ml and 2.5 PFU/g, respectively. 
Number of mice with detectable virus per number tested. 
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a mucoid nasal discharge, difficulty in breathing, and 
lethargy which developed 2-3 days later. The severity 
of these signs progressed and the rabbits were euthana- 
tized 7 days after infection due to acute dyspnea. Lung 
tissue of both rabbits was removed and analyzed for the 
presence of RPV and RPVA35 in order to determine any 
viremic selectivity. Both viruses were readily obtained 
from the lungs of both rabbits with RPV showing a slight 
(4=1 and D1) predominance. 
DISCUSSION 
RPV-infected cells secrete two major proteins that are 
readily detected by Coomassie staining or 35S-labeling 
(Fig. 1) of infected cell supernates. The smaller of the 
two proteins was characterized as the RPV homolog of 
VCP, the complement inhibitory protein described in W- 
WR (Kotwal etaL, 1990; McKenzie etaL, 1992). The larger 
(35 kDa) of these two secreted proteins, the subject of 
this study, is present in RPV but missing in the media 
from ceils infected with either W-WR or CPV. 
A determination of the N-terminal amino acid se- 
quence of this RPV 35-kDa protein was determined which 
allowed subsequent identification of the protein and 
mapping of the gene. Computer analysis of the gene 
sequence suggested it was similar if not identical to a 
previously described, major secreted 35-kDa protein 
from W-Lister-infected cells (Patel et al., 1990). The 35- 
kDa W-Lister protein is encoded by a gene located at 
both ends of the viral genome within the inverted terminal 
repetitions (ITRs) and results in the gene being diploid. 
The promoter (PT.~) that regulates the gene in W-Lister 
results in 35-kDa protein expression at both early and 
late times of infection and has been extensively charac- 
terized in W-WR. The P7.5 promoter, so named because 
in W-WR, the ORF encodes a protein of only 7.5 kDa 
(Wittek et al., 1980b; Wittek and Moss, 1980; Wittek et 
al., 1980a; Cooper et aL, 1981a), is also located within 
both ITRs of the viral DNA. It is reasonable to assume 
that the W-Lister and RPV 35-kDa proteins are more 
"complete" forms of the W-WR 7.5-kDa protein (Figs. 1 
and 4). The lack of homology between the gene encoding 
the 35-kDa major secreted protein of wt RPV to any pro- 
teins of known function makes it difficult to assign a role 
for this protein during infection. 
The 35-kDa protein has been conserved among some 
(W-Copenhagen, CPV-BR, W-Lister, and variola virus) 
but not all orthopoxviruses and Shope fibroma virus 
(SFV), a leporipoxvirus (Fig. 3). Based on the analogy to 
the W-Lister sequence which contains a signal peptide 
(Fig. 3), one would predict protein secretion in other vi- 
ruses, for example, CPV. However, one puzzling feature 
is that no secreted protein of 35 kDa was found in CPV- 
infected cells even though the nucleotide sequence sug- 
gests that the CPV protein would be expected to be 
nearly the same size (Fig. 3) and contains a hydrophobic 
N-terminal region that could function as a signal peptide. 
CPV does, however, secrete a unique, smaller protein 
(Fig. 1) absent in both RPV and W-WR infections. 
Whether this is related to the 35-kDa protein is not 
known. Alternatively, a "down" promoter mutation for the 
CPV 35 kDa gene might lead to significantly lower levels 
of protein production in CPV-infected cells. In W-Copen- 
hagen, the protein lacks a signal peptide and in W-WR 
is truncated to a 7.5-kDa polypeptide due to a frame-shift 
mutation in the gene. 
These differences in the 35-kDa gene between various 
poxviruses make it clear that at least in cell culture, the 
35-kDa protein is "non-essential" for viral growth. Other 
poxvirus genes nonessential for growth in tissue culture 
have been described, most of which are located toward 
either end of the viral genome (Meyer et al., 1980; Meyer 
and Rothe, 1980; Panicali etaL, 1981; Perkus etaL, 1986; 
Moss etaL, 1981; Lake and Cooper, 1980). Indeed, exten- 
sive terminal deletions of viral DNA still result in a virus 
capable of growing in some cells in culture (Konishi et 
al., 1992). In many cases, though, these "nonessential" 
genes have been shown to influence viral pathogenesis 
in the animal. It is possible, therefore, that retention of 
this secreted protein in RPV and W-Lister might reflect 
a rather specific biological role of the protein in these 
viruses. Wild-type RPV has been a valuable system in 
which to evaluate the contribution of different genes in 
the virulence of the RPV (Thompson et aL, 1993; Bloom 
et aL, 1991). Therefore, mice infected intranasally with 
either wt RPV or RPVA35 were examined. Few differ- 
ences between RPV and RPVA35 at higher infectious 
doses were noted. However, at lower doses reproduc- 
ible, more severe disease symptoms were noted in mice 
infected with RPVz&35 (Fig. 5) which correlated with more 
rapid weight loss, even at a dose of 103 PFU at which 
RPV did not produce any detectable disease (Thompson 
et al., 1993). Differences due to slight variations in viral 
titers which might produce these results were minimized 
by titering viral stocks both before and after each experi- 
ment. Though these differences are reproducible, having 
been noted in at least two independent experiments, the 
enhanced virulence noted in the RPVA35 infections is 
still quite small, and attributing significance to such small 
differences should be done with caution. For example, 
there are passage differences between wt RPV and any 
mutant generated from that stock. There is also the possi- 
bility of spontaneous mutations arising in nonintended 
regions of the genome. Finally, the flanking regions of 
the pD357 plasmid used to disrupt the 35-kDa gene were 
derived from W-Lister, not RPV. While these flanking W- 
Lister sequences are undoubtedly related to those of 
RPV, any sequence differences could lead to unantici- 
pated changes in virulence. 
There are, however, examples where disruption of a 
gene leads to enhanced virulence. Once such example 
is the W-WR IL-1/~ binding protein gene mutant (Alcami 
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and Smith, 1992). In that case, it was suggested that 
elimination of viral IL-1/g binding activity could result in 
elevated IL-1 levels which in turn could lead to the en- 
hanced viral growth and toxicity observed (Alcami and 
Smith, 1992). However, no more virus was recovered 
from mice infected with RPVA35 as compared to RPV, 
which indicated that any enhanced severity of the dis- 
ease was not due to more efficient virus replication (Ta- 
ble 1). One possibility is that the RPVz~35 mutant infec- 
tion could lead to the increased synthesis of one or more 
cytokines to toxic levels which could result in manifesta- 
tion of systemic disease. The limited results obtained 
measuring the levels of IL-6 and TNF in the lungs and 
sera of infected animals indicated that this does not 
seem to be the case. 
RPV, unlike W-WR, is a very lethal rabbit pathogen 
(Bedson and Duckworth, 1963). Therefore, we also com- 
pared RPV and RPVA35 pathogenesis in rabbits by 
studying the lesions produced after intradermal inocula- 
tion and viremic efficiency. No differences were detected 
between the lesions produced by either RPV or RPVA35 
even after microscopic examination. Both viruses spread 
efficiently to the lungs and skin with RPV being slightly 
more efficient. Calculations of accurate LDsos in rabbits 
will be difficult due to a great variability among different 
animals unless the effect is profound. Therefore, the only 
observed biological effect of the 35-kDa protein may be 
to delay somewhat the onset of clinical symptoms of 
disease in mice (Fig. 5). Nevertheless, it is clear that 
under the conditions evaluated, the 35-kDa protein is 
a major secreted protein which, unlike other poxvirus 
secreted proteins, for example, the soluble TNF receptor 
(Smith et aL, 1991; Upton et aL, 1991), the complement 
C4b binding protein homolog (Kotwal et al., 1990), and 
the complement-related viral protein encoded by the BSR 
0RF of W (Engelstad et al., 1992; Isaacs et a/., 1992b) 
and RPV (Martinez-Pomares et al., 1993), does not ap- 
pear to contribute to enhanced viral virulence. Rather, 
the 35-kDa protein, like the interleukin 1/5' receptor 
(Spriggs et aL, 1992; Alcami and Smith, 1992), appears 
to act to retard the onset of clinical symptoms. Any viral 
gene which delays the demise of an animal could result 
in enhanced propagation of the pathogen and hence be 
advantageous. 
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